Anticoagulation for prevention and treatment of cancer-related venous thromboembolism

British Journal of Haematology

Volumn 161, Issue 6, 2013, Pages 764-777

  Barsam, Sarah J ^a   Patel, Raj ^a   Arya, Roopen ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Malignancy; Oral anticoagulants; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 12; DALTEPARIN; DEXAMETHASONE; ENOXAPARIN; FONDAPARINUX; HEPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE; THROMBIN; THROMBIN INHIBITOR; THROMBOPLASTIN; TINZAPARIN; VASCULOTROPIN; WARFARIN;

ANGIOGENESIS; ANTICOAGULANT THERAPY; BLEEDING; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RELATED VENOUS THROMBOEMBOLISM; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CYTOKINE RELEASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; LOW DRUG DOSE; MULTIPLE MYELOMA; OUTPATIENT CARE; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOSIS PREVENTION; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEMORRHAGE; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK; VENOUS THROMBOEMBOLISM;

EID: 84878505234     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12314     Document Type: Review

References (91)

1. Ageno, W., Grimwood, R., Limbiati, S., Dentali, F., Steidl, L. & Wells, P.S. (2005) Home-treatment of deep vein thrombosis in patients with cancer. Haematologica, 90, 220-224.
2. Agnelli, G. (1997) Venous thromboembolism and cancer: a two way clinical association. Journal of Thrombosis and Haemostasis, 78, 117-120.
3. Agnelli, G. & Verso, M. (2011) Management of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis, 9, 316-324.
4. Agnelli, G., Bergqvist, D., Cohen, A.T., Gallus, A.S. & Gent, M.; PEGASUS investigators. (2005) Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. British Journal of Surgery, 92, 1212-1220.
5. Agnelli, G., Bolis, G., Capussotti, L., Scarpa, R.M., Tonelli, F., Bonizzoni, E., Moia, M., Parazzini, F., Rossi, R., Sonaglia, F., Valarani, B., Bianchini, C. & Gussoni, G. (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Annals of Surgery, 243, 89-95.
6. Agnelli, G., Gussoni, G., Bianchini, C., Verso, M., Mandalà, M., Cavanna, L., Barni, S., LaBianca, R., Buzzi, F., Scambia, G., Passalacqua, R., Ricci, S., Gasparini, G., Lorusso, V., Bonizzoni, E. & Tonato, M. (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet, 10, 943-949.
7. Agnelli, G., George, D.J., Kakkar, A.K., Fisher, W., Lassen, M.R., Mismetti, P., Mouret, P., Chaudhari, U., Lawson, F. & Turpie, A.G.G.; for the SAVE-ONCO Investigators (2012) Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer. New England Journal of Medicine, 366, 601-609.
8. Akl, E.A., Terrenato, I., Barba, M., Sperati, F., Muti, P. & Schünemann, H.J. (2008) Extended perioperative thromboprophylaxis in patients with cancer. A systematic review. Thrombosis and Haemostasis, 100, 1176-1180.
9. Akl, E.A., Labedi, N., Barba, M., Terrenato, I., Sperati, F., Muti, P. & Schunemann, H. (2011) Anticoagulation for the longterm treatment of venous thromboembolism in patients with cancer. Cochrane Database of Systematic Reviews, 6, CD006650.
10. Alikhan, R., Cohen, A.T., Combe, S., Samama, M.M., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Olsson, C. & Turpie, A.G.G. (2003) Benefit of enoxaparin in medical patients. Blood Coagulation and Fibrinolysis., 14, 341-346.
11. Altinbas, M., Coskun, H.S., Er, O., Ozkan, M., Eser, B., Unal, A., Cetin, M. & Soyuer, S. (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis, 2, 1266-1271.
12. Anaissie, E.J., Coleman, E.A., Goodwin, J.A., Kennedy, R.L., Lockhart, K.D., Stewart, C.B., Coon, S.K., Bailey, C. & Barlogie, B. (2012) Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer, 15, 549-557.
13. Ay, C., Dunkler, D., Simanek, R., Thaler, J., Koder, S., Marosi, C., Zielinski, C. & Pabinger, I. (2011) Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology, 29, 2099-2103.
14. Barni, S., Labianca, R., Agnelli, G., Bonizzoni, E., Verso, M., Mandalà, M., Brighenti, M., Petrelli, F., Bianchini, C., Perrone, T. & Gasparini, G. (2011) Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine, 9, 179-186.
15. Bauersachs, R., Berkowitz, S.D., Brenner, B., Buller, H.R., Decousus, H., Gallus, A.S., Lensing, A.W., Misselwitz, F., Prins, M.H., Raskob, G.E., Segers, A., Verhamme, P., Wells, P., Agnelli, G., Bounameaux, H., Cohen, A., Davidson, B.L., Piovella, F. & Schellong, S. (2010) Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine, 363, 2499-2510.
16. Bergqvist, D. (2007) Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis. Journal of Surgical Oncology, 95, 167-174.
17. Bergqvist, D., Agnelli, G., Cohen, A.T., Eldor, A., Nilsson, P.E., Le Moigne-Amrani, A. & Dietrich-Neto, F.; ENOXACAN II Investigators. (1997) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double blind randomized multicentre trial with venographic assessment. British Journal of Surgery, 84, 1099-1103.
18. Bergqvist, D., Agnelli, G., Cohen, A.T., Eldor, A., Nilsson, P.E., Le Moigne-Amrani, A. & Dietrich-Neto, F.; for the ENOXACAN II Investigators. (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. New England Journal of Medicine, 346, 975-980.
19. Blom, J.W., Vanderschoot, J.P., Oostindiër, M.J., Osanto, S., van der Meer, F.J. & Rosendaal, F.R. (2006) Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. Journal of Thrombosis and Haemostasis, 4, 529-535.
20. Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock, J., Trelle, S., Weingart, O., Bayliss, S., Djulbegovic, B., Bennett, C.L., Langensiepen, S., Hyde, C. & Engert, A. (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute, 98, 708-714.
21. Bona, R.D., Hickey, A.D. & Wallace, D.M. (1997) Efficacy and safety of oral anticoagulation in patients with cancer. Thrombosis and Haemostasis, 8, 137-140.
22. Buller, H.R., Davidson, B.L., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M.H., Raskob, G., Segers, A.E., Cariou, R., Leeuwenkamp, O. & Lensing, A.W., Matisse Investigators. (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine, 140, 867-873.
23. Carrier, M., Le Gal, G., Cho, R., Tierney, S., Rodger, M. & Lee, A.Y. (2009) Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. Journal of Thrombosis and Haemostasis, 7, 760-765.
24. Cavo, M., Zamagni, E., Cellini, C., Tosi, P., Cangini, D., Cini, M., Valdrè, L., Palareti, G., Masini, L., Tura, S. & Baccarani, M. (2002) Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood, 100, 2272-2273.
25. Chew, H.K., Wun, T., Harvey, D., Zhou, H. & White, R.H. (2006) The incidence of venous thromboembolism and its effect on survival among patients with common cancer. Archives of Internal Medicine, 166, 458-464.
26. Clagett, G.P. & Reisch, J.S. (1988) Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Annals of Surgery, 208, 227-240.
27. Decousus, H., Leizorovicz, A., Parent, F., Page, Y., Tardy, B., Girard, P., Laporte, S., Faivre, R., Charbonnier, B., Barral, F.-G., Huet, Y. & Simonneau, G.; for the Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. (1998) A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. New England Journal of Medicine, 338, 409-416.
28. Decousus, H., Leizorovicz, A., Parent, F., Page, Y., Tardy, B., Girard, P., Laporte, S., Faivre, R., Charbonnier, B., Barral, F.-G., Huet, Y. & Simonneau, G., for the Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. (2005) Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation, 112, 416-422.
29. Deitcher, S.R., Kessler, C.M., Merli, G., Rigas, J.R., Lyons, R.M. & Fareed, J. ONCENOX Investigators. (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/Hemostasis, 12, 389-396.
30. Di Nisio, M., Porreca, E., Ferrante, N., Otten, H.M., Cuccurullo, F. & Rutjes, A.W.S. (2012) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Systematic Review, 2, CD008500.
31. Dolovich, L.R., Ginsberg, J.S., Douketis, J.D., Holbrook, A.M. & Cheah, G. (2000) A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Archives of Internal Medicine, 160, 181-188.
32. van Doormaal, F.F., Raskob, G.E., Davidson, B.L., Decousus, H., Gallus, A., Lensing, A.W., Piovella, F., Prins, M.H. & Büller, H.R. (2009) Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis., 101, 762-769.
33. Dvorak, H.F., Quay, S.C., Orenstein, N.S., Dvorak, A.M., Hahn, P., Bitzer, A.M. & Carvalho, A.C. (1981) Tumor shedding and coagulation. Science, 212, 923-924.
34. Falanga, A. & Marchetti, M. (2009) Venous thromboembolism in the hematologic malignancies. Journal of Clinical Oncology, 27, 4848-4857.
35. Falanga, A., Marchetti, M. & Vignoli, A. (2012) Coagulation and cancer: biological and clinical aspects. Journal of Thrombosis and Haemostasis, 11, 223-333.
36. Farge, D., Debourdeau, P., Beckers, M., Baglin, C., Bauersachs, R.M., Brenner, B., Brilhante, D., Falanga, A., Gerotzafias, G.T., Haim, N., Kakkar, A.K., Khorana, A.A., Lecumberri, R., Mandala, M., Marty, M., Monreal, M., Mousa, S.A., Noble, S., Pabinger, I., Prandoni, P., Prins, M.H., Qari, M.H., Streiff, M.B., Syrigos, K., Bounameaux, H. & Buller, H.R. (2012) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis, 11, 56-70.
37. Fujita, J., Mestre, J.R., Zeldis, J.B., Subbaramaiah, K. & Dannenberg, A.J. (2001) Thalidomide and its analogues inhibit lipopolysaccharide-mediated linduction of cyclooxygenase-2. Clinical Cancer Research, 7, 3349-3355.
38. Gitter, M.J., Jaeger, T.M., Petterson, T.M., Gersh, B.J. & Silverstein, M.D. (1995) Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clinic Proceedings, 70, 725-733.
39. Haas, S.K., Freund, M., Heigener, D., Heilmann, L., Kemkes-Matthes, B., von Tempelhoff, G.F., Melzer, N. & Kakkar, A.K.; for the TOPIC Investigators. (2010) Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clinical and Applied Thrombosis/Hemostasis, 2, 159-165.
40. Hull, R.D., Pineo, G.F., Brant, R.F., Mah, A.F., Burke, N., Dear, R., Wong, T., Cook, R., Solymoss, S., Poon, M.C. & Raskob, G.; for the LITE Trial Investigators. (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine, 119, 1062-1072.
41. Hutten, B., Prins, M., Gent, M., Ginsberg, J., Tijsen, J.G.P. & Buller, H.R. (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. Journal of Clinical Oncology, 18, 3078-3083.
42. Jarrett, B.P., Dougherty, M.J. & Calligaro, K.D. (2002) Inferior vena cava filters in malignant disease. Journal of Vascular Surgery., 36, 704-707.
43. Kahn, S.R., Lim, W., Dunn, A.S., Cushman, M., Dentali, F., Akl, E.A., Cook, D.J., Balekian, A.A., Klein, R.C., Le, H., Schulman, S. & Murad, M.H. (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141, e195S-e226S.
44. Kakkar, A.K., Levine, M.N., Kadziola, Z., Lemoine, N.R., Low, V., Patel, H.K., Rustin, G., Thomas, M., Quigley, M. & Williamson, R.C.N. (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology, 22, 10.
45. Kearon, C., Akl, E.A., Comerota, A.J., Prandoni, P., Bounameaux, H., Goldhaber, S.Z., Nelson, M.E., Wells, P.S., Gould, M.K., Dentali, F., Crowther, M. & Kahn, S.R. (2012) Antithrombotic therapy for VTE disease: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e419S-e494S.
46. Khorana, A.A. (2010) Venous thromboembolism and prognosis in cancer. Thrombosis Research, 125, 490-493.
47. Khorana, A.A. (2012) Cancer-associated thrombosis: updates and controversies. American Society of Hematology Education Program Book, 2012, 626-630.
48. Khorana, A.A., Francis, C.W., Culakova, E. & Lyman, G.H. (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer, 104, 2822-2829.
49. Khorana, A.A., Ahrendt, S.A., Ryan, C.K., Francis, C.W., Hruban, R.H., Hu, Y.C., Hostetter, G., Harvey, J. & Taubman, M.B. (2007) Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clinical Cancer Research, 13, 2870-2875.
50. Khorana, A.A., Kuderer, N.M., Culakova, E., Lyman, G.H. & Francis, C.W. (2008) Development and validation of a predictive model for chemotherapy associated thrombosis. Blood, 111, 4902-4907.
51. Khorana, A.A., Spyropoulos, A.C., Zwicker, J., Lyman, G.H. & Francis, C.W. (2012) Preventing VTE in outpatients with cancer. Chest, 142, 265-266.
52. Kuderer, N.M., Khorana, A.A., Lyman, G.H. & Francis, C.W. (2007) A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer, 110, 1149-1161.
53. Kuderer, N.M., Ortel, T.L. & Francis, C.W. (2009) Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. Journal of Clinical Oncology, 27, 4902-4911.
54. Kuenen, B.C., Levi, M., Meijers, J.C., van Hinsbergh, V.W., Berkhof, J., Kakkar, A.K., Hoekman, K. & Pinedo, H.M. (2003) Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. Journal of Clinical Oncology, 2, 2192-2198.
55. Kvolik, S., Jukic, M., Matijevic, M., Marjanovic, K. & Glavas-Obrovac, L. (2010) An overview of coagulation disorders in cancer patients. Surgical Oncology, 19, 33-46.
56. Laporte, S., Mismetti, P., De′cousus, H., Uresandi, F., Otero, R., Lobo, J.L. & Monreal, M. (2008) Clinical predictors for fatal pulmonary embolism in 15 520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation, 117, 1711-1716.
57. Larocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., Patriarca, F., Cavo, M., Peccatori, J., Catalano, L., Carella, A.M., Cafro, A.M., Siniscalchi, A., Crippa, C., Petrucci, M.T., Yehuda, D.B., Beggiato, E., Di Toritto, T.C., Boccadoro, M., Nagler, A. & Palumbo, A. (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 26, 933-939.
58. Lebeau, B., Chastang, C., Brechot, J.M., Capron, F., Dautzenberg, B., Delaisements, C., Mornet, M., Brun, J., Hurdebourcq, J.P. & Lemarie, E. (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer: "Petites Cellules" Group. Cancer, 74, 38-45.
59. Lee, A.Y. (2012) Treatment of established thrombotic events in patients with cancer. Thrombosis Research, 129, S146-S153.
60. Lee, A.Y. & Kamphuisen, P.W. (2012) Epidemiology and prevention of catheter-related thrombosis in patients with cancer. Journal of Thrombosis and Haemostasis, 10, 1491-1499.
61. Lee, A.Y., Levine, M.N., Baker, R.I., Bowden, C., Kakkar, A.K., Prins, M., Rickles, F.R., Julian, J.A., Haley, S., Kovacs, M.J. & Gent, M. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine, 349, 146-153.
62. Leizorovicz, A., Cohen, A.T., Turpie, A.G., Olsson, C.G., Vaitkus, P.T. & Goldhaber, S.Z. (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation, 110, 874-879.
63. Levine, M., Gent, M., Hirsh, J., Leclerc, J., Anderson, D., Weitz, J., Ginsberg, J., Turpie, A.G. & Kovacs, M. (1996) A comparison of low molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine, 334, 677-681.
64. Levine, M.N., Gu, C., Liebman, H.A., Escalante, C.P., Solymoss, S., Deitchman, D., Ramirez, L. & Julian, J. (2012) A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. Journal of Thrombosis and Haemostasis, 10, 807-814.
65. Levitan, N., Dowlati, A., Remick, S.C., Tahsildar, H.I., Sivinski, L.D., Beyth, R. & Rimm, A.A. (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine (Baltimore), 78, 285-291.
66. Lyman, G., Khorana, A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., Kakkar, A., Kuderer, N., Levine, M., Liebman, H., Mendelson, D., Raskob, G., Somerfield, M., Thodiyil, P., Trent, D. & Francis, C. (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. Journal of Clinical Oncology, 25, 5490-5505.
67. Mandala, M., Falanga, A. & Roila, F. (2010) Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. Annals of Oncology, 21, 274-276.
68. Marchetti, M., Diani, E., Cate, H. & Falanga, A. (2012) Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography. Haematologica, 97, 1173-1180.
69. van Marion, A.M., Auwerda, J.J., Lisman, T., Sonneveld, P., de Maat, M.P., Lokhorst, H.M. & Leebeek, F.W. (2008) Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leukaemia Research, 32, 1078-1084.
70. Matsuo, K., Carter, C.M., Ahn, E.H., Prather, C.P., Eno, M.L., Im, D.D. & Rosenshein, N.B. (2012) Inferior Vena Cava Filter Placement and Risk of Hematogenous Distant Metastasis in Ovarian Cancer. American Journal of Clinical Oncology, May 24 [Epub ahead of print].
71. Merkow, R.P., Bilimoria, K.Y., McCarter, M.D., Cohen, M.E., Barnett, C.C., Raval, M.V., Caprini, J.A., Gordon, H.S., Ko, C.Y. & Bentrem, D.J. (2011) Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Annals of Surgery, 254, 131-137.
72. Meyer, G., Marjanovic, Z., Valcke, J., Lorcerie, B., Gruel, Y., Solal-Celigny, P., Le Maignan, C., Extra, J.M., Cottu, P. & Farge, D. (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine, 162, 1729-1735.
73. Palareti, G., Legnani, C., Lee, A., Manotti, C., Hirsh, J., D'Angelo, A., Pengo, V., Moia, M. & Coccheri, S. (2000) A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Journal of Thrombosis and Haemostasis, 84, 805-810.
74. Palumbo, A., Cavo, M., Bringhen, S., Zamagni, E., Romano, A., Patriarca, F., Rossi, D., Gentilini, F., Crippa, C., Galli, M., Nozzoli, C., Ria, R., Marasca, R., Montefusco, V., Baldini, L., Elice, F., Callea, V., Pulini, S., Carella, A.M., Zambello, R., Benevolo, G., Magarotto, V., Tacchetti, P., Pescosta, N., Cellini, C., Polloni, C., Evangelista, A., Caravita, T., Morabito, F., Offidani, M., Tosi, P. & Boccadoro, M. (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a Phase III, open-label, randomized trial. Journal of Clinical Oncology, 29, 986-993.
75. Prandoni, P., Lensing, A.W., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., Marchiori, A., Sabbion, P., Prins, M.H., Noventa, F. & Girolami, A. (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood, 100, 3484-3488.
76. Rasmussen, M.S., Jorgensen, L.N., Wille-Jørgensen, P., Nielsen, J.D., Horn, A., Mohn, A.C., Sømod, L. & Olsen, B. (2006) Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. Journal of Thrombosis and Haemostasis., 4, 2384-2390.
77. Rasmussen, M.S., Jørgensen, L.N. & Wille-Jørgensen, P. (2009) Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database of Systematic Reviews, 1, CD004318.
78. Ruíz-Giménez, N., Suárez, C., González, R., Nieto, J.A., Todolí, J.A., Samperiz, A.L., Monreal, M. & Investigators, R.I.E.T.E. (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thrombosis Haemostasis, 100, 26-31.
79. Samama, M.M., Cohen, A.T., Darmon, J.-Y., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Nguyen, H., Olsson, C.G., Turpie, A. & Graham, W. (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. The New England Journal of Medicine, 341, 793-800.
80. Siegal, D.M. & Garcia, D. (2012) Anticoagulants in cancer. Journal of Thrombosis and Haemostasis, 10, 2230-2241.
81. Sorensen, H.T., Mellemkjaer, L., Olsen, J.H. & Baron, J.A. (2000) Prognosis of cancers associated with venous thromboembolism. New England Journal of Medicine, 343, 1846-1850.
82. Streiff, M.B.; for the National Comprehensive Cancer Center Network. (2010) The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thrombosis Research, 125, S128-S133.
83. Streiff, M.B., Bockenstedt, P.L., Cataland, S.R., Chesney, C., Millenson, A.Z., Neff, A.T., Ortel, T.L., Smith, J.L., Yee, G.C., Jones, K.A., Kuderer, N., Lee, J.T., Garcia-Aguilar, M.M., Goldhaber, S.Z., Hassoun, H., Hendrie, P., Eby, B.C., Fanikos, J., Fogarty, P.F. & Gao, S. (2011) Venous thromboembolic disease. Journal of National Comprehensive Cancer Network, 9, 714-777.
84. Tesselaar, M.E., Romijn, F.P., Van Der Linden, I.K., Prins, F.A., Bertina, R.M. & Osanto, S. (2007) Microparticle-associated tissue factor activity: a link between cancer and thrombosis? Journal of Thrombosis and Haemostasis, 5, 520-527.
85. Traby, L., Kaider, A., Schmid, R., Kranz, A., Quehenberger, P., Kyrle, P.A. & Eichinger, S. (2010) The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial. Thrombosis and Haemostasis, 104, 92-99.
86. Trousseau, A. (1865) Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris 3, 2nd edn. The Sydenham Society, Paris, France, pp. 654-712.
87. Trujillo-Santos, J., Prandoni, P., Rivron-Guillot, K., Román, P., Sánchez, R., Tiberio, G. & Monreal, M. (2008) Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. Journal of Thrombosis and Haemostasis, 6, 251-255.
88. Verso, M., Gussoni, G. & Agnelli, G. (2010) Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. Journal of Thrombosis and Haemostasis, 8, 1649-1651.
89. Wallace, M.J., Jean, J.L., Gupta, S., Eapen, G.A., Johnson, M.M., Ahrar, K., Madoff, D.C., Morello, F.A., Murthy, R. & Hicks, M.E. (2004) Use of inferior vena caval filters and survival in patients with malignancy. Cancer, 101, 1902-1907.
90. White, R.H., Beyth, R.J., Zhou, H. & Romano, P.S. (1999) Major bleeding after hospitalization for deep-venous thrombosis. American Journal of Medicine, 107, 414-424.
91. Zacharskia, L.R., Prandoni, P. & Monreal, M. (2005) Warfarin versus low-molecular-weight heparin therapy in cancer patients. The Oncologist, 10, 72-79.